Clinical Trial Update: Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, and anti-tumor activity of ATO-101 in patients with non-muscle-invasive bladder cancer. The study status is N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ATO-101

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Bladder Cancer | Phase 1 | Status: NOT_YET_RECRUITING